BIOMAT Database Logo BIOMAT Database Logo

Mechanisms of Klebsiella pneumoniae resistance to complement-mediated killing. 1992

S Merino, and S Camprubí, and S Albertí, and V J Benedí, and J M Tomás
Departamento de Microbiología, Universidad de Barcelona, Spain.

The different mechanisms of Klebsiella pneumoniae resistance to complement-mediated killing were investigated by using different strains and isogenic mutants previously characterized for their surface components. We found that strains from serotypes whose K antigen masks the lipopolysaccharide (LPS) molecules (such as serotypes K1, K10, and K16) fail to activate complement, while strains with smooth LPS exposed at the cell surface (with or without K antigen) activate complement but are resistant to complement-mediated killing. The reasons for this resistance are that C3b binds far from the cell membrane and that the lytic final complex C5b-9 (membrane attack complex) is not formed. Isogenic rough mutants (K+ or K-) are serum sensitive because they bind C3b close to the cell membrane and the lytic complex (C5b-9) is formed.

UI MeSH Term Description Entries
D007711 Klebsiella pneumoniae Gram-negative, non-motile, capsulated, gas-producing rods found widely in nature and associated with urinary and respiratory infections in humans. Bacillus pneumoniae,Bacterium pneumoniae crouposae,Hyalococcus pneumoniae,Klebsiella pneumoniae aerogenes,Klebsiella rhinoscleromatis
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D001770 Blood Bactericidal Activity The natural bactericidal property of BLOOD due to normally occurring antibacterial substances such as beta lysin, leukin, etc. This activity needs to be distinguished from the bactericidal activity contained in a patient's serum as a result of antimicrobial therapy, which is measured by a SERUM BACTERICIDAL TEST. Activities, Blood Bactericidal,Activity, Blood Bactericidal,Bactericidal Activities, Blood,Bactericidal Activity, Blood,Blood Bactericidal Activities
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003179 Complement C3b The larger fragment generated from the cleavage of COMPLEMENT C3 by C3 CONVERTASE. It is a constituent of the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb), and COMPLEMENT C5 CONVERTASES in both the classical (C4b2a3b) and the alternative (C3bBb3b) pathway. C3b participates in IMMUNE ADHERENCE REACTION and enhances PHAGOCYTOSIS. It can be inactivated (iC3b) or cleaved by various proteases to yield fragments such as COMPLEMENT C3C; COMPLEMENT C3D; C3e; C3f; and C3g. C3b Complement,C3bi,Complement 3b,Complement Component 3b,Inactivated C3b,iC3b,C3b, Complement,C3b, Inactivated,Complement, C3b,Component 3b, Complement
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015938 Complement Membrane Attack Complex A product of COMPLEMENT ACTIVATION cascade, regardless of the pathways, that forms transmembrane channels causing disruption of the target CELL MEMBRANE and cell lysis. It is formed by the sequential assembly of terminal complement components (COMPLEMENT C5B; COMPLEMENT C6; COMPLEMENT C7; COMPLEMENT C8; and COMPLEMENT C9) into the target membrane. The resultant C5b-8-poly-C9 is the "membrane attack complex" or MAC. Complement Complex C5b-9,Membrane Attack Complex,C 5b-9,C5b-8-poly-C9,C5b-9,Cytolytic Terminal Complement Complex,Terminal Complement Complex,C5b 8 poly C9,Complement Complex C5b 9,Complement Complex, Terminal,Complex, Terminal Complement

Related Publications

S Merino, and S Camprubí, and S Albertí, and V J Benedí, and J M Tomás
Complement resistance mechanisms of Klebsiella pneumoniae.
October 2016, Immunobiology,
S Merino, and S Camprubí, and S Albertí, and V J Benedí, and J M Tomás
Colistin resistance mutations in phoQ can sensitize Klebsiella pneumoniae to IgM-mediated complement killing.
August 2023, Scientific reports,
S Merino, and S Camprubí, and S Albertí, and V J Benedí, and J M Tomás
Dynamics of human complement-mediated killing of Klebsiella pneumoniae.
November 2010, American journal of respiratory cell and molecular biology,
S Merino, and S Camprubí, and S Albertí, and V J Benedí, and J M Tomás
Complement mediated Klebsiella pneumoniae capsule changes.
January 2020, Microbes and infection,
S Merino, and S Camprubí, and S Albertí, and V J Benedí, and J M Tomás
Aeromonas salmonicida resistance to complement-mediated killing.
December 1994, Infection and immunity,
S Merino, and S Camprubí, and S Albertí, and V J Benedí, and J M Tomás
Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing.
December 2008, Vaccine,
S Merino, and S Camprubí, and S Albertí, and V J Benedí, and J M Tomás
Complement killing of clinical Klebsiella pneumoniae isolates is serum concentration dependent.
May 2023, Microbes and infection,
S Merino, and S Camprubí, and S Albertí, and V J Benedí, and J M Tomás
Quinolone resistance mechanisms in Klebsiella pneumoniae.
January 1995, Drugs,
S Merino, and S Camprubí, and S Albertí, and V J Benedí, and J M Tomás
Toxoplasma gondii: mechanism of resistance to complement-mediated killing.
February 1989, Journal of immunology (Baltimore, Md. : 1950),
S Merino, and S Camprubí, and S Albertí, and V J Benedí, and J M Tomás
Gramine sensitizes Klebsiella pneumoniae to tigecycline killing.
February 2024, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Copied contents to your clipboard!